Creo Medical Group's endoscopic device gains European approval

Creo Medical Group’s endoscopic device gained approval in the European Union for microwave energy keeping the company on track for the device’s launch later this year.

The company’s device, Speedboat RS2, has received CE mark approval for microwave energy to add to the devices previous CE award for radiofrequency.

In clinical trials Speedboat RS2 has applied microwave energy to coagulate bleeds in the colon in 30 patients and the company claims that it is the first device to use microwave energy with radiofrequency.

A publication of the study has been accepted for this May’s Digestive Disease Week, a meeting of physicians, researchers and industry figures in gastroenterology, hepatology, endoscopy and gastrointestinal surgery

Creo is also developing Speedboat RS2 as part of its Croma electrosurgery system to remove large and flat pre-cancerous and cancerous lesions in the bowel which are typically referred for surgical removal.

Chief executive Craig Gulliford said: "We remain on track to initiate the soft launch of the Speedboat product later this year, in line with our strategy at IPO to translate this surgery sparing technology into routine clinical practice and expect this to be followed by the introduction of a range of devices for the therapeutic endoscopy market.

“Surgical endoscopy, a billion dollar plus market, is an emerging field and with the Croma platform and range of endoscopic devices, we believe that we are well positioned to become a leader in this growing market."